Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.
Study Type
OBSERVATIONAL
Enrollment
676
Non-interventional,observational Firmagon given by prescription according to SPC
Investigational Site, Heinrich-Rieger-Str. 15
Aalen, Germany
Investigational Site, Weidenfelder Straße 1
Aalen, Germany
Investigational Site
Abensberg, Germany
Investigational Site
Ahaus, Germany
Investigational Site
Ahrensburg, Germany
Investigational Site
duration of the PSA progression-free survival
Time frame: open (until therapy end or stop)
1. testosterone levels
Time frame: open (until therapy end or stop)
2. number of ADRs and SUSARs
Time frame: open (until therapy end or stop)
3. quality of life
Time frame: open (until therapy end or stop)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alsdorf, Germany
Investigational Site
Alsfeld, Germany
Investigational Site
Altenburg, Germany
Investigational Site
Andernach, Germany
Investigational Site, Endresstraße 12
Ansbach, Germany
...and 220 more locations